PharmaDossier
Manufacturing

How to Verify an Unchanged Compendial Method at a New QC Lab

A receiving-lab worksheet for verifying an unchanged USP–NF chromatographic method for a tablet, with the U.S. CGMP records and FDA guidance behind each check.

Ran Chen
Ran Chen
13 min read · Published · Source-cited

Before a U.S. finished-drug quality-control (QC) lab uses an unchanged USP–NF chromatographic procedure for routine tablet testing, it must verify that the procedure is suitable under the lab’s actual conditions of use. The current monograph identifies the procedure, a sending-lab report may show prior performance, and a local system suitability pass shows that the system met the checks performed. The verification decision depends on how much of the intended use those records cover for this tablet and this lab (21 CFR § 211.194, 21 CFR § 211.165).

Start by matching the effective monograph and local procedure to the tablet formulation and strength, the purpose and range of the test, and the receiving lab’s equipment, reagents and preparation. Then identify the performance questions that remain open. FDA recommends generating verification data under a protocol with predefined criteria for the relevant checks. The worksheet below shows how to trace each question to evidence and record what remains to be verified (FDA guidance, § VI.C, USP <1226> public introduction).

What the new lab has to establish

U.S. current good manufacturing practice (CGMP) requires the laboratory record to identify each method used to test a sample. Under § 211.194(a)(2), the method statement ordinarily points to data supporting accuracy and reliability for the product tested. For an unmodified procedure in the current United States Pharmacopeia–National Formulary (USP–NF), naming the method and its reference is sufficient for that statement. The same subsection requires actual-use suitability verification for all methods used (21 CFR § 211.194).

Section 211.165(e) requires the firm to establish and document the accuracy, sensitivity, specificity and reproducibility of its test methods. It expressly allows that work and documentation to follow § 211.194(a)(2). For the receiving lab, this means the record has to support the method as applied to the tablet, including any aspect of the preparation or measurement where suitability is still uncertain (21 CFR § 211.165, 21 CFR § 211.194).

In section VI.C (printed page 8) of its July 2015 guidance, FDA recommends generating verification information under a protocol and including it in submissions within the guidance’s scope. Set the acceptance criteria before testing and describe the equipment, reagents, chromatographic conditions, system suitability, and sample preparation and stability as relevant. The procedure and intended use guide the selection of performance checks (FDA guidance, § VI.C).

The public introduction to USP–NF General Chapter <1226> describes first-use verification with the personnel, equipment and reagents available in the laboratory. It calls for relevant data from selected performance characteristics in place of repeating validation. It also describes a first-use framework for procedures the lab is introducing, rather than a retroactive review of procedures that have already been successfully established (USP <1226> public introduction).

Part 211 supplies the binding U.S. CGMP requirements. The FDA documents provide nonbinding recommendations. The USP chapter citations cover their public introductions. Use the applicable official monograph, General Notices, referenced chapters and any approved application commitments to establish the controlled requirements for the actual procedure.

Which existing records cover this product and lab?

Review the effective monograph, the sending-lab report and the local system suitability record against the exact claim the lab wants to make. For example, the claim might be that the local procedure can measure potency in a film-coated tablet at its commercial strength. The records for that claim may differ from those for measuring a specified impurity in the same product.

Start with the monograph and approved local standard operating procedure (SOP). Record the effective revision and check which preparation, chromatographic conditions and acceptance criteria apply. Identify any separate product-specific limit in the approved specification. That comparison can reveal a low-level measurement question even when the official procedure itself is unchanged.

Read the scope and data behind the sending lab’s conclusion. A report from that lab alone can supply prior performance evidence. A transfer report may also contain results generated at the receiving site. Check which lab ran the procedure, which version and materials it used, and which concentration range it evaluated. Results from both labs on the intended tablet may cover relevant parts of the local assessment if the conditions and criteria align. A sending-site-only report on the same tablet can inform protocol design and still leave a local performance question (USP <1224> public introduction, FDA guidance, § VIII.B.2).

Record what the local system suitability sequence actually challenged. FDA describes system suitability as confirmation that the integrated system functions correctly at the time of use. In the example, the pass is based on standard injections. Those results can support the applicable run checks while leaving tablet extraction, matrix interference and low-level quantitation open. FDA guidance, § IV.H. For the related evidence questions, see how to review a passing HPLC system suitability result and how to verify a USP Reference Standard lot.

For each record, capture the report or sequence identifier, the method revision and test purpose, the material or formulation and strength, the range or limit studied, and the lab conditions. Link the result to the relevant preparation, equipment and reagent or reference-standard records where those details affect the claim. A report title or a summary conclusion alone can leave the reviewer unable to establish what the data cover.

Record on handWhat to carry into the assessmentWhat to check before relying on it
Current USP–NF monographOfficial procedure and applicable compendial criteria. Map the effective version to the local SOP.Confirm the procedure as implemented and the applicable product specification. Determine whether the intended tablet or limit raises a performance question.
Sending-lab verification or transfer reportRelevant prior data and any documented receiving-site results within their tested scope.Identify the executing lab, method version, tablet matrix and strength, range, and preparation. Locate the underlying data for any claim being carried forward.
Passing local system suitabilityEvidence that the specified checks were met for the sequence and conditions documented.Check whether matrix, preparation or performance near the actual limit was challenged. A pass on working standards alone leaves those questions open.

Choose performance checks for the intended test

Choose checks by asking how a result could be wrong for the intended test. An assay may need evidence that the main peak can be measured in the presence of the tablet’s excipients. A quantitative impurity test may need evidence that the procedure can measure an impurity at the lower end of the range it must report. FDA § VI.C and the USP <1226> introduction support selecting characteristics for the procedure and use. ICH Q2(R2) Table 1 provides a validation reference for which characteristics are typically relevant to different test purposes (FDA guidance, § VI.C, USP <1226> public introduction, ICH Q2(R2), Table 1).

FDA says robustness studies may be omitted for compendial assays that are followed without deviations. That recommendation concerns robustness in that setting. Assess other relevant characteristics, including any unresolved question about the matrix, sample preparation or a tighter product limit (FDA guidance, § VI.C).

The two examples use hypothetical products and test conditions. The intended use, controlled procedure and product specification provide the basis for the protocol’s actual acceptance criteria and study design.

Illustration 1: Possible assay interference in a tablet matrix

A lab is adopting an unchanged high-performance liquid chromatography (HPLC) assay for a film-coated tablet. The sending laboratory’s report covers a capsule formulation, and the local suitability sequence passed using standards. A component of the tablet coating could contribute a signal near the active ingredient’s peak. The solid tablet may also present a different extraction question from the material in the report. Those are two distinct ways the assay result could be biased.

For specificity, the protocol could compare a blank, an appropriate placebo or representative matrix, a standard and a prepared tablet sample. Define in advance what level of interference at the assay peak would be acceptable, and record why that criterion supports the assay. If extraction is in question, choose an accuracy check that includes sample preparation. Include a precision check if preparation variability is also a concern. A spike added only after extraction can help assess response in the prepared matrix but supplies no direct test of recovery through the original tablet preparation (FDA guidance, § VI.C, ICH Q2(R2), §§ 3.1 and 3.3).

Illustration 2: A tighter quantitative impurity limit

In the second example, an unchanged compendial procedure will be used for quantitative related-substances testing. The product has a tighter impurity specification, with an applicable reporting threshold below the range evaluated in the sending-lab report. Record the product’s reporting threshold and acceptance limit separately when both apply. The reporting threshold drives how low the lab needs a quantitative result, while the acceptance limit is used to judge whether the result meets specification.

A passing check at the working standard concentration leaves performance at the lower reporting level unanswered. The protocol can assess the quantitation limit and confirm acceptable accuracy and precision near the low end of the intended reportable range, along with specificity against relevant matrix peaks. Set the criteria so the evidence covers the applicable reporting threshold and supports a result at the specification limit. Finding a signal addresses detection. Reporting a quantity also requires evidence of acceptable accuracy and precision (FDA guidance, § VI.C, ICH Q2(R2), §§ 2.3 and 3.2.3, and Table 1).

If the tablet-preparation problem prompts a proposed solvent change outside the applicable compendial allowances, assess it as a method change. For a modification to an established method used in testing, § 211.194(b) requires a record of the reason and data showing that the changed method yields results at least as accurate and reliable for the material tested. Identify the affected performance characteristics and assess applicable reporting obligations. If the change would replace an FDA-approved analytical procedure, also evaluate the guidance on alternative procedures (21 CFR § 211.194, ICH Q2(R2), § 2.2, FDA guidance, §§ VIII.A, VIII.B.1 and VIII.C).

Compare verification, transfer, and new-method validation

Start with the decision the receiving lab needs to make. A record can support more than one decision when the underlying data address each question. For instance, a transfer study can contribute to first-use verification if the receiving-site data cover the intended product, procedure and performance question.

FDA describes comparative interlaboratory studies as typical for transfer. ICH Q2(R2) discusses comparative analysis, partial or full revalidation, and justification for omitting additional transfer experiments when appropriate. Validation of a new noncompendial procedure instead establishes performance for the procedure’s intended purpose, such as release testing, stability testing, or both as applicable. See FDA guidance, §§ VI.A and VIII.B.2 and ICH Q2(R2), §§ 1.2 and 2.1–2.2. For study design and interlaboratory criteria, see the analytical method transfer guide.

DecisionSource and supporting evidenceCommon gap
Verify first use of the unchanged compendial method21 CFR §§ 211.194(a)(2) and 211.165(e), FDA § VI.C, and USP <1226>. Match selected checks and predefined criteria to the product and actual conditions of use.The local pass covered only system checks on standards, or the product-specific question was outside the sending report.
Qualify the receiving lab through transferUSP <1224>, FDA § VIII.B.2, and ICH Q2(R2) § 2.2. Document the receiving lab’s ability to perform the procedure, typically with comparative results or another justified approach.The report covers another formulation, revision or limit, or lacks evidence applicable to the receiving lab.
Validate a new noncompendial procedureFDA § VI.A and ICH Q2(R2) §§ 1.1–1.2, 2.1 and 3. Establish the relevant performance characteristics and criteria for the intended purpose in a justified validation study.A prior procedure’s data leave the new method or its intended range uncharacterized.
Assess a modification to the established procedure21 CFR § 211.194(b), FDA §§ VIII.A–C as applicable, and ICH Q2(R2) § 2.2. Record why it changed, compare accuracy and reliability, and assess revalidation and applicable application obligations.A change in preparation may affect recovery or specificity even if the chromatographic settings and run checks are unchanged.

Document what the evidence supports before routine use

A reviewer should be able to trace the verification conclusion to the applicable criteria and original laboratory records. Section 211.194(a)(4)–(8) calls for complete test data identified to the material and lot, calculations, results compared with established standards, the analyst’s initials or signature and test date, and a second person’s initials or signature documenting review of original records for accuracy, completeness and compliance. In the worksheet, record the identifiers that let someone retrieve those records and reconcile them with the protocol and report (21 CFR § 211.194).

Use this worksheet for one defined test and proposed use at a time. The entries show what to record, which evidence would support the decision, and when the decision stays open. The examples use descriptive criteria to show their purpose. The applicable procedure, product specification and site quality system govern the actual criteria, study size and approval roles.

Worksheet fieldA. Tablet assay with a matrix questionB. Impurity test at a tighter limitC. Proposed sample-preparation change
Procedure and revisionEffective USP–NF assay procedure and corresponding receiving-lab SOP.Effective USP–NF impurity procedure and corresponding receiving-lab SOP.Established procedure and exact preparation step proposed for change.
Intended use and productPotency assay for the film-coated tablet at the specified strength.Quantitative impurities for the intended formulation and applicable reporting and specification levels.The intended test and tablet strength for which the change would apply.
Local conditionsLocal instrument and column, analyst, tablet preparation, reagents and standard lot.Local instrument and detector, reagents, standards and tablet preparations.Local preparation equipment and proposed change to the solvent or other preparation condition.
Prior record and its coverageSending report covers a capsule. Local suitability passes on standards.Sending report covers a higher quantitative level. Local suitability passes at the working standard concentration.Previous reports cover the established preparation. Identify which results are useful as the comparator.
Characteristic and predefined criterionSpecificity for the active peak, with interference criteria. Add a recovery criterion if preparation is in question and a precision criterion if variability also matters.Quantitation limit, accuracy and precision at the intended low end, and specificity as applicable. Base criteria on the level the method must report.Select affected characteristics and establish criteria to demonstrate results at least as accurate and reliable for the tablet.
Evidence referenceLink the sequence and original chromatograms to the identified control and tablet preparations and calculations.Link low-level comparison data to the actual standards or spiked matrix, calculations and applicable limits.Record the reason for the change, the comparison against the established procedure and the relevant change assessment.
Conclusion or open gapKeep tablet specificity open until the reviewed matrix data meet the protocol criteria.Keep use at the tighter limit open until reviewed low-range data support it.Route for change assessment and applicable regulatory review before adopting the modified procedure.

Resolve gaps before routine use

Compare the intended use with the claim the data actually support. If reviewed evidence establishes specificity for the assay, close that performance question for the defined tablet and lab. Keep any other assay questions open, as well as the separate impurity procedure’s lower-range question until the corresponding evidence is reviewed. Record the boundary explicitly so a later reviewer can tell which testing the conclusion covers.

  • For a coverage gap, identify the missing evidence and the protocol check that would address it. For example, if the different tablet coating was the only untested risk, focus on interference at the relevant peak and explain why the rest of the applicable evidence can be used.

  • For a failed check, retain the original results and refer the failure through the site’s quality procedures. Record the criterion, impacted use and disposition of the investigation before concluding the method is suitable. If the response is to change the procedure, assess the change and its impact before adoption.

  • Keep the method-use conclusion with the laboratory verification record. Batch testing and release are separate decisions under § 211.165(a) and (d), which address batch conformance and acceptance criteria (21 CFR § 211.165).

Sources

  • U.S. Government Publishing Office, April 2025 annual CFR edition. Binding U.S. CGMP provisions for method identification, actual-use suitability, complete records and modifications. The cited provisions were cross-checked against the live eCFR display (21 CFR § 211.194).

  • U.S. Government Publishing Office, April 2025 annual CFR edition. Binding U.S. CGMP requirements for documented method performance and batch conformance, cross-checked against the live eCFR display (21 CFR § 211.165).

  • FDA, July 2015 final, nonbinding guidance. See § IV.H for system suitability, § VI.A for noncompendial validation, § VI.C for compendial verification, and §§ VIII.A–C for change, comparability, transfer and reporting considerations (Analytical Procedures and Methods Validation for Drugs and Biologics).

  • United States Pharmacopeia, 2019 public introduction. Describes first-use verification and the selection of relevant performance characteristics (USP–NF <1226> Verification of Compendial Procedures).

  • United States Pharmacopeia, 2017 public introduction. Defines transfer as documented qualification of a receiving laboratory (USP–NF <1224> Transfer of Analytical Procedures).

  • FDA, March 2024 final, nonbinding ICH guidance. Sections 1.1–1.2 and 2.1 address fitness for intended purpose, §§ 2.2–2.3 discuss transfer, changes and reportable range, and § 3 and Table 1 address performance characteristics (Q2(R2) Validation of Analytical Procedures).

Ran Chen
Contributing Editor
Ran Chen

Founder, PharmaDossier. Life-sciences operator covering market access, specialty pharma, biosimilars, and regulated healthcare growth.

Follow on LinkedIn →